Overview

Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, double-blind (evaluator-blind), vehicle-controlled study of 50 enrolled subjects. Adult subjects (greater than 18 years old) who present with a mildly infected diabetic foot ulcer (IDSA criteria) having full thickness (i.e., through the dermis but not involving joint capsule, tendon, and bone). Subjects must also provide informed consent and meet all other entry criteria to be enrolled and randomly assigned to receive PluroGel N or PluroGel vehicle.
Phase:
Phase 2
Details
Lead Sponsor:
PluroGen Therapeutics, Inc
Collaborator:
Arkios BioDevelopment International